NRX Pharmaceuticals Inc (NASDAQ: NRXP) Announces Partnership with the Israel Institute for Biological Research

NRX Pharmaceuticals Inc (NASDAQ: NRXP) has announced a partnership with the Israel Institute for Biological Research to complete the development and commercialization of the COVID vaccine.

MoU for development of COVID: NRX Pharmaceuticals has signed a memorandum of understanding with the Israel Government to license development, manufacturing, and market rights for a Coronavirus vaccine developed by the Israel Institute of Biological research. The vaccine is based on the approval by FDA (The U.S Food and Drug Administration) platform that was further optimized by Israel Institute for Biological Research and target for diagnosis COVID-19. As per NRx, the company anticipates rapid and affordable scale-up and manufacturing. The vaccine will initially be delivered by traditional injection. The company is honored to be selected by the Israel Government to take the vaccine development ahead. COVID vaccines are increasingly challenged by rapid mutation (variation) of the Coronavirus, as per the company. NRx aims to develop a vaccine that can rapidly scale at low cost to serve the requirements of both the developed and the developing nations. As the virus mutates (expand with various challenges), the company focuses on building through first-generation vaccines to boost immunity. The company is focused on COVID by including a vaccine platform that can scale at high speed and low cost.

Treatment of COVID-19 patients: NRx Pharmaceuticals and Quantum Leap Healthcare Collaborative have started treating patients with inhaled (Aviptadil) ZYESAMIO, in the I-SPY COVID Trial, a phase 2 adaptive platform aimed at improving treatment for critically ill COVID-19 patients. The trial is focused on the efficient assessment of multiple investigational agents simultaneously. The objective is to test a variety of agents for the treatment of COVID-19 patients. Specifically, the goal is to search for the agents that significantly impact reducing mortality and duration of mechanical ventilation. In the I-SPY COVID Trial, inhaled ZYESAMIO will treat critically ill patients to determine whether inhaled administration can achieve similar results.

Leave a Comment

Your email address will not be published.